Don’t use bevacizumab for its various oncologic indications.
Based on the most recent literature assessing the effectiveness of bevacizumab, the benefit expected from this agent for its various oncologic indications is in the order of a few weeks of survival gained. Since the cost of bevacizumab is high and its incremental...
Don’t prefer bioresorbable coronary stents over traditional drug-eluting stents.
The recent development of bioresorbable coronary stents (Bioresorbable Vascular Scaffolds, BVS) represent a promising therapeutic option as compared with traditional drug-eluting stents (DES). However, based on the most recent evidence currently available, BVS (the...
Don’t prescribe MF-59 adjuvated influenza vaccine in elderly people.
The population at increased risk for developing influenza is represented by subjects aged ≥65 years or suffering from co-morbidities. However, defining the “place in therapy” of the different types of influenza vaccine is difficult because comparative studies based on...
Don’t propose any type of palliative chemotherapy in the end-of-life setting.
The results of numerous prospective clinical studies indicate that chemotherapy administered to patients with metastatic cancer in their last 30 days of life is ineffective and leads, particularly in the last week of life, to an increased utilization of intensive care...The campaign DOING MORE DOES NOT MEAN DOING BETTER – CHOOSING WISELY ITALY is promoted by Italy’s Slow Medicine
Recent Comments